Figure 7.

The C-terminal of MSI1 suppress xenograft tumor growth in GBM and PDAC animal models. (A) A schematic presentation showing the design of animal experiment with in vivo delivery of Flag-C-term (10 µg using in vivo-jetPEI in vivo nucleic acid delivery reagent). Xenograft tumor size was monitored from day 2 after injection of Flag-control or Flag-C-term. (B) Immunocompromised mice were subcutaneously transplanted with 05MG/Flag-MSI1 stable cells. Two days after tumor size reached 50 mm³, mice were intratumorally injected with 10 µg of Flag-control or Flag-C-term for 3 rounds with 2-day intervals. Tumor size was then monitored for 22 days. The expression of MIS1-C-term in the xenograft tumor tissue was assessed by Western blot. (C) Immunocompromised mice were subcutaneously transplanted with MIA-PaCa2 cells. Two days after tumor size reached 50 mm³, mice were intratumorally injected with Flag-control or Flag-C-term for 3 rounds with 2 days interval. Tumor size was then monitored for 22 days. The expression of MIS1-C-term in the xenograft tumor tissue was assessed by Western blot. (D) Tumor tissue were harvested and homogenized for Western blotting. Whole-tumor lysate were subjected to co-immunoprecipitation assay for endogenous AGO2 and MSI1 protein-protein interaction. Data represent the mean ± S.D. of three independent experiments performed in triplicate. Tumor tissues of (E) 05MG/GBM cells and (F) MIA-PaCa2/pancreatic cells from MSI1-C-term injected xenografts were immunostained with anti-Flag antibodies to observer the expression of MSI1-C-term in the tumors.